Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
NCT06662539 on ClinicalTrials.gov · last registry update 2026-03-23
An unusually large phase 2: 493 participants, more than double the 114 typical for the stage. The sponsor logged completion for 30 September 2025. Primary outcome, as filed: Percent change from baseline in body weight to Week 28. petrelintide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Drug
- petrelintide
- Sponsor
- Zealand Pharma
- Sponsor type
- Industry
- Enrollment
- 493
- Started
- 2024-12-09
- Primary completion
- 2025-09-30 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent change from baseline in body weight to Week 28
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the petrelintide page for this molecule’s full trial and approval history.